Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50908 |
Name | myelodysplastic syndrome |
Definition | A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myelodysplastic syndrome |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 mutant | N/A | myelodysplastic syndrome | not applicable | detail... |
NRAS G12X | N/A | myelodysplastic syndrome | not applicable | detail... |
NRAS G13X | N/A | myelodysplastic syndrome | not applicable | detail... |
NRAS Q61X | N/A | myelodysplastic syndrome | not applicable | detail... |
IDH2 R140Q | N/A | myelodysplastic syndrome | not applicable | detail... |
IDH2 R172X | N/A | myelodysplastic syndrome | not applicable | detail... |
FLT3 exon 14 ins | N/A | myelodysplastic syndrome | not applicable | detail... |
FLT3 D835X | N/A | myelodysplastic syndrome | not applicable | detail... |
IDH2 R140X | Enasidenib | myelodysplastic syndrome | predicted - sensitive | detail... |
IDH2 R172X | Enasidenib | myelodysplastic syndrome | predicted - sensitive | detail... |
IDH2 R172X | Azacitidine + Enasidenib | myelodysplastic syndrome | predicted - sensitive | detail... |
IDH2 R140X | Azacitidine + Enasidenib | myelodysplastic syndrome | predicted - sensitive | detail... |
FLT3 exon 15 ins | N/A | myelodysplastic syndrome | not applicable | detail... |
IDH1 mutant | Ivosidenib | myelodysplastic syndrome | sensitive | detail... |
IDH1 R132C | Ivosidenib | myelodysplastic syndrome | sensitive | detail... |
IDH1 R132G | Ivosidenib | myelodysplastic syndrome | sensitive | detail... |
IDH1 R132H | Ivosidenib | myelodysplastic syndrome | sensitive | detail... |
IDH1 R132L | Ivosidenib | myelodysplastic syndrome | sensitive | detail... |
IDH1 R132S | Ivosidenib | myelodysplastic syndrome | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00801489 | Phase II | Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin | Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias | Recruiting | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01211457 | Phase Ib/II | Sapacitabine + Venetoclax Decitabine + Sapacitabine | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes | Unknown status | USA | 0 |
NCT01685411 | Phase 0 | Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam | Busulfan and Cyclophosphamide Followed By ALLO BMT | Terminated | USA | 0 |
NCT01773395 | Phase II | Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus | GVAX vs. Placebo for MDS/AML After Allo HSCT | Terminated | USA | 0 |
NCT01804101 | Phase I | CPX-351 | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01892371 | Phase Ib/II | Azacitidine + Quizartinib Cytarabine + Quizartinib | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT01898793 | Phase Ib/II | m-ceNK cells Aldesleukin + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Nogapendekin alfa inbakicept | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT01915498 | Phase Ib/II | Enasidenib | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation | Completed | USA | FRA | 0 |
NCT02019069 | Phase II | CPX-351 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02115295 | Phase II | Cladribine + Cytarabine + Idarubicin Midostaurin | Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) | Recruiting | USA | 0 |
NCT02117219 | Phase I | Azacitidine + Durvalumab | Phase 1 Study to Evaluate MEDI4736 in MDS | Completed | USA | GBR | FRA | DEU | 0 |
NCT02117297 | Phase II | Gemtuzumab ozogamicin | SCT Plus Immune Therapy in Average Risk AML/MDS | Completed | USA | 0 |
NCT02193958 | Phase Ib/II | FF-10501-01 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | Completed | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02221310 | Phase II | Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | Completed | USA | 0 |
NCT02228525 | Phase II | Selinexor | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes | Completed | USA | 0 |
NCT02240706 | Phase II | BI 836858 | Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes | Terminated | USA | DEU | 0 |
NCT02250937 | Phase II | Cladribine Busulfan Busulfan + Venetoclax Fludarabine | Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT02267863 | Phase I | APTO-253 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Terminated | USA | 0 |
NCT02269579 | Phase II | CPX-351 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | Withdrawn | USA | 0 |
NCT02273102 | Phase I | Tranylcypromine + Tretinoin | Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) | Completed | USA | 0 |
NCT02281084 | Phase II | Azacitidine Azacitidine + Durvalumab | Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02367456 | Phase Ib/II | Azacitidine + Glasdegib | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients | Completed | USA | GBR | FRA | DEU | CAN | BEL | 0 |
NCT02462252 | Phase II | anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone | Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02472145 | Phase III | Decitabine Decitabine + Talacotuzumab | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | Completed | USA | TUR | SWE | POL | ISR | GBR | FRA | ESP | DEU | BEL | AUS | 3 |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |
NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02494167 | Phase I | MultiTAA-specific T cells | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | Recruiting | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02508870 | Phase I | Azacitidine Atezolizumab | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Completed | USA | 0 |
NCT02530034 | Phase I | Hu8F4 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT02530463 | Phase II | Nivolumab Azacitidine Ipilimumab | Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Active, not recruiting | USA | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02553941 | Phase I | Azacitidine + Ibrutinib | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02556931 | Phase II | Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | Completed | USA | 0 |
NCT02562443 | Phase III | Rigosertib Sodium | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE) | Terminated | USA | SWE | POL | ITA | ISR | IRL | HUN | HRV | GBR | FRA | EST | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 3 |
NCT02564536 | Phase I | Decitabine + Pacritinib | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | Withdrawn | 0 | |
NCT02576301 | Phase Ib/II | Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS | Unknown status | USA | 0 |
NCT02598661 | Phase III | Imetelstat | Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | 3 |
NCT02610777 | Phase II | Azacitidine MLN4924 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Completed | USA | NLD | ITA | ISR | IRL | FRA | ESP | DEU | CZE | CAN | BGR | BEL | 0 |
NCT02641002 | Phase I | CC-90002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT02666950 | Phase II | Adavosertib Cytarabine | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02676323 | Phase Ib/II | Cytarabine + Fludarabine + Leucovorin + Panobinostat | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT02677922 | Phase Ib/II | Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | Active, not recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 2 |
NCT02683395 | Phase I | PLX51107 | A Study of PLX51107 in Advanced Malignancies | Terminated | USA | 0 |
NCT02684162 | Phase II | Guadecitabine | SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) | Completed | USA | 0 |
NCT02717884 | Phase Ib/II | Cytarabine + Tranylcypromine + Tretinoin | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA) | Unknown status | DEU | 0 |
NCT02719574 | Phase I | Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT02721875 | Phase I | Azacitidine Volasertib | Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | Terminated | 1 | |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02724163 | Phase III | Gemtuzumab ozogamicin Busulfan + Fludarabine Cytarabine Cytarabine + Fludarabine Cytarabine + Daunoxome Busulfan + Cyclophosphamide Cytarabine + Mitoxantrone | International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01) | Recruiting | NZL | IRL | GBR | FRA | CHE | AUS | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02728050 | Phase Ib/II | Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone | Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02743611 | Phase I | Rimiducid BPX-701 | Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms | Terminated | USA | 0 |
NCT02749708 | Phase Ib/II | IRX5183 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT02756572 | Phase I | Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02775903 | Phase II | Azacitidine Azacitidine + Durvalumab | An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) | Completed | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 1 |
NCT02779777 | Phase II | Tipifarnib | Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | Terminated | USA | 0 |
NCT02786485 | Phase I | Rimiducid Rivogenlecleucel | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Active, not recruiting | USA | 0 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02795520 | Phase Ib/II | OTS167 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | Terminated | USA | 0 |
NCT02807558 | Phase II | Azacitidine + Tamibarotene Tamibarotene | A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | FRA | 0 |
NCT02829840 | Phase Ib/II | Azacitidine + Ponatinib | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | Withdrawn | 0 | |
NCT02841540 | Phase I | H3B-8800 | A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia | Terminated | USA | ITA | FRA | ESP | BEL | 2 |
NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Terminated | USA | 0 |
NCT02848001 | Phase I | CC-90009 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | Terminated | USA | NOR | GBR | FRA | ESP | CAN | 0 |
NCT02890329 | Phase I | Decitabine + Ipilimumab | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02907359 | Phase III | Cytarabine Guadecitabine | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | Completed | USA | SWE | POL | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | 2 |
NCT02909972 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02923986 | Phase Ib/II | BP1001 + Dasatinib | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | Withdrawn | USA | 0 |
NCT02935361 | Phase Ib/II | Atezolizumab + Guadecitabine | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | Active, not recruiting | USA | 0 |
NCT02936752 | Phase I | Entinostat + Pembrolizumab | Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure | Active, not recruiting | USA | 0 |
NCT02942290 | Phase II | Azacitidine Azacitidine + Venetoclax | A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS) | Active, not recruiting | USA | ITA | GBR | FRA | DEU | CAN | AUS | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02966782 | Phase I | Azacitidine + Venetoclax Venetoclax | A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure | Completed | USA | DEU | AUS | 0 |
NCT02979366 | Phase I | MIK665 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | Completed | USA | FRA | ESP | AUS | 0 |
NCT02981914 | Phase 0 | Pembrolizumab | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT02989844 | Phase II | Nogapendekin alfa inbakicept | QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT | Completed | USA | 0 |
NCT03011034 | Phase II | Talacotuzumab Daratumumab | Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | Completed | USA | NLD | ITA | ESP | BEL | 1 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03042689 | Phase I | Regorafenib | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | Completed | USA | 0 |
NCT03047993 | Phase Ib/II | Azacitidine + Telaglenastat | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03066648 | Phase I | Decitabine + Spartalizumab Decitabine + Sabatolimab + Spartalizumab Decitabine + Sabatolimab | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | Completed | USA | NLD | GBR | FRA | FIN | ESP | DEU | AUS | 0 |
NCT03067571 | Phase II | Daratumumab | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT03069469 | Phase I | Vimseltinib | Study of DCC-3014 in Patients With Advanced Malignancies | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT03072043 | Phase Ib/II | APR-246 + Azacitidine | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | Completed | USA | 0 |
NCT03074006 | Phase Ib/II | Vactosertib | Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
NCT03075826 | Phase II | Guadecitabine | A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | Completed | USA | 0 |
NCT03092674 | Phase II | Cytarabine + Decitabine Azacitidine + Midostaurin Decitabine Azacitidine + Nivolumab Azacitidine | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03094637 | Phase II | Azacitidine + Pembrolizumab | Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS) | Active, not recruiting | USA | 0 |
NCT03113643 | Phase I | Azacitidine + Tagraxofusp-erzs + Venetoclax Azacitidine + Tagraxofusp-erzs | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | USA | 0 |
NCT03128034 | Phase Ib/II | Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Suspended | USA | 0 |
NCT03151304 | Phase II | Azacitidine + Pracinostat Azacitidine | A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes | Terminated | USA | 0 |
NCT03164057 | Phase II | Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03187288 | Phase I | CFI-400945 | A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | CAN | 0 |
NCT03214562 | Phase Ib/II | Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax | Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT03214666 | Phase Ib/II | GTB-3550 TriKE | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Terminated | USA | 0 |
NCT03238248 | Phase II | Azacitidine + MLN4924 | Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors | Completed | USA | 0 |
NCT03248479 | Phase I | Azacitidine + Hu5F9-G4 Hu5F9-G4 | Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies | Terminated | USA | GBR | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03268954 | Phase III | Azacitidine + MLN4924 Azacitidine | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) | Completed | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 5 |
NCT03286114 | Phase I | Pembrolizumab | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Terminated | USA | 0 |
NCT03306264 | Phase III | Decitabine Decitabine and Cedazuridine | Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML | Completed | USA | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | 0 |
NCT03326310 | Phase I | Azacitidine + Selumetinib | Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia | Recruiting | USA | 0 |
NCT03326921 | Phase I | Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT03358719 | Phase I | Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03359460 | Phase I | Ibrutinib + Lenalidomide | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03383575 | Phase II | Azacitidine + Enasidenib Enasidenib | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03386513 | Phase Ib/II | IMGN632 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03393611 | Phase I | anti-thymocyte globulin + Fludarabine + Melphalan CPX-351 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03397173 | Phase II | Azacitidine + Vitamin C | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | Completed | USA | 0 |
NCT03404193 | Phase II | Decitabine + Venetoclax | Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03404726 | Phase I | BAY2402234 | A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies | Terminated | USA | FRA | 0 |
NCT03417154 | Phase II | Cyclophosphamide + Nivolumab | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | Completed | USA | 0 |
NCT03459859 | Phase I | Cytarabine + MLN4924 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | Completed | USA | 0 |
NCT03465540 | Phase I | AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | Terminated | USA | ITA | GRC | FRA | AUS | 1 |
NCT03471260 | Phase Ib/II | Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | Recruiting | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03503409 | Phase II | Ivosidenib | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | Active, not recruiting | ITA | FRA | 0 |
NCT03503968 | Phase Ib/II | MDG1011 | TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | Terminated | DEU | 0 |
NCT03515512 | Phase I | Enasidenib | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT03516591 | Phase I | AMV-564 | A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes | Completed | USA | 0 |
NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
NCT03537599 | Phase Ib/II | Daratumumab | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | Completed | USA | 0 |
NCT03564821 | Phase I | Ivosidenib | IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT03572764 | Phase I | CPX-351 | CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03573310 | Phase I | JNJ-64619178 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | Active, not recruiting | USA | ISR | ESP | DEU | CAN | 0 |
NCT03594955 | Phase Ib/II | SAR440234 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | Terminated | USA | FRA | 0 |
NCT03603964 | Phase II | Guadecitabine | Guadecitabine Extension Study | Terminated | USA | ITA | ESP | DNK | CAN | AUT | 3 |
NCT03613532 | Phase I | Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT03614728 | Phase I | Azacitidine + GSK3326595 GSK3326595 | Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Terminated | USA | CAN | 0 |
NCT03661307 | Phase Ib/II | Decitabine + Quizartinib + Venetoclax | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03670966 | Phase Ib/II | BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus | 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome | Suspended | USA | 0 |
NCT03672539 | Phase I | Gemtuzumab ozogamicin CPX-351 + Gemtuzumab ozogamicin | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03699475 | Phase II | Rimiducid + Rivogenlecleucel Cyclophosphamide | Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE) | Terminated | USA | 0 |
NCT03735446 | Phase I | Cytarabine + Etoposide + Mitoxantrone + Prexasertib | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | Terminated | USA | 0 |
NCT03744390 | Phase II | Enasidenib | IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome | Active, not recruiting | FRA | 0 |
NCT03745716 | Phase III | APR-246 + Azacitidine Azacitidine | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | Completed | USA | FRA | 0 |
NCT03746041 | Phase I | Abaloparatide + Bevacizumab | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | Completed | USA | 0 |
NCT03770429 | Phase I | Ceralasertib | AZD6738 for Patients With Progressive MDS or CMML | Recruiting | USA | 0 |
NCT03772925 | Phase I | Belinostat + MLN4924 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03787498 | Phase I | PLX2853 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03807063 | Phase I | Rimiducid Rivogenlecleucel | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03814005 | Phase I | Azacitidine + MLN4924 | A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment | Completed | USA | ESP | 0 |
NCT03816319 | Phase I | TAK-243 | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts | Recruiting | CAN | 0 |
NCT03839771 | Phase III | Ivosidenib Enasidenib | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) | Active, not recruiting | SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | EST | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT03843528 | Phase I | Azacitidine + Vorinostat | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | Recruiting | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03884829 | Phase I | CYC140 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Terminated | USA | 0 |
NCT03885947 | Phase I | Cyclophosphamide + Fludarabine + Thiotepa | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | Completed | USA | 0 |
NCT03886662 | Phase Ib/II | LB-100 | A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | Recruiting | USA | 0 |
NCT03886831 | Phase I | PRT543 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Completed | USA | 0 |
NCT03896269 | Phase I | CPX-351 | CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT03912064 | Phase I | Ipilimumab | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Active, not recruiting | USA | 0 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Active, not recruiting | CAN | 0 |
NCT03915379 | Phase I | JNJ-67571244 | A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Completed | USA | ESP | DEU | 0 |
NCT03927261 | Phase I | PRGN-3006 | PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS | Active, not recruiting | USA | 0 |
NCT03929211 | Phase Ib/II | CPI-613 + Hydroxychloroquine | CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome | Withdrawn | USA | 0 |
NCT03931291 | Phase II | APR-246 + Azacitidine | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | Completed | USA | 0 |
NCT03932643 | Phase I | ONC201 | ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT03940352 | Phase I | Siremadlin + Venetoclax Sabatolimab + Siremadlin | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Terminated | USA | ITA | FIN | ESP | DEU | AUS | 1 |
NCT03946670 | Phase II | Decitabine + Sabatolimab Azacitidine Azacitidine + Sabatolimab Decitabine | A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | Completed | USA | TUR | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | 4 |
NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Active, not recruiting | USA | 0 |
NCT03957876 | Phase II | CPX-351 | CPX-351 Therapy for MDS After Hypomethylating Agent Failure | Terminated | USA | 0 |
NCT03969446 | Phase I | Decitabine + Pembrolizumab | Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | Recruiting | USA | 0 |
NCT03974217 | Phase I | Talazoparib | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | Recruiting | USA | 0 |
NCT04013880 | Phase Ib/II | Decitabine and Cedazuridine + Olutasidenib | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT04021368 | Phase I | RVU120 | SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Active, not recruiting | USA | POL | 0 |
NCT04022785 | Phase I | Azacitidine + PLX51107 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT04027309 | Phase III | Midostaurin Gilteritinib | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) | Active, not recruiting | SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT04047641 | Phase II | Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04055844 | Phase II | Decitabine + Ruxolitinib | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | Completed | USA | 0 |
NCT04079296 | Phase Ib/II | ASP7517 | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | Completed | USA | 1 |
NCT04092179 | Phase Ib/II | Enasidenib + Venetoclax | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | Terminated | CAN | 0 |
NCT04103879 | Phase II | ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil | US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Active, not recruiting | USA | NLD | 0 |
NCT04109482 | Phase Ib/II | Cyclophosphamide + Decitabine + Fludarabine + MB-102 | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. | Terminated | USA | 0 |
NCT04128020 | Phase I | Azacitidine + Nivolumab Nivolumab | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | Withdrawn | 0 | |
NCT04128748 | Phase Ib/II | CPX-351 + Quizartinib | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04139434 | Phase I | LP-108 | Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | ESP | 0 |
NCT04140487 | Phase Ib/II | Azacitidine + Gilteritinib + Venetoclax | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Recruiting | USA | 0 |
NCT04146038 | Phase II | Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | Completed | USA | 0 |
NCT04160052 | Phase Ib/II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04167696 | Phase I | CYAD-02 Cyclophosphamide + Fludarabine | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) | Recruiting | USA | BEL | 0 |
NCT04167917 | Phase I | NTX-301 | NTX-301 in MDS/AML | Recruiting | USA | 0 |
NCT04187703 | Phase I | Azacitidine + Decitabine | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies | Recruiting | USA | 0 |
NCT04227847 | Phase I | SEA-CD70 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Recruiting | USA | NLD | 0 |
NCT04239157 | Phase II | Azacitidine + Canakinumab | Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT04243785 | Phase I | BTX-A51 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04245397 | Phase I | SX-682 | SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy | Recruiting | USA | 0 |
NCT04256317 | Phase III | ASTX030 ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine | A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML | Active, not recruiting | USA | CAN | 0 |
NCT04264806 | Phase II | ARGX-110 + Azacitidine Azacitidine | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | Withdrawn | TUR | ITA | GBR | FRA | ESP | DEU | CHE | BRA | AUS | 2 |
NCT04266301 | Phase III | Azacitidine Azacitidine + Sabatolimab | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2) | Completed | USA | TUR | NLD | LTU | LBN | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 15 |
NCT04278768 | Phase I | CA-4948 | An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Recruiting | USA | POL | ITA | ISR | FRA | ESP | DEU | CZE | 0 |
NCT04284228 | Phase Ib/II | Cyclophosphamide + Fludarabine + NEXI-001 T Cells | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | Active, not recruiting | USA | 0 |
NCT04313881 | Phase III | Azacitidine Azacitidine + Hu5F9-G4 | Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE) | Terminated | USA | TUR | POL | NZL | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 2 |
NCT04326764 | Phase III | Panobinostat | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Terminated | NLD | DEU | 0 |
NCT04361058 | Phase I | Nivolumab | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | Withdrawn | USA | 0 |
NCT04401748 | Phase III | Azacitidine + Venetoclax Azacitidine | Safety And Efficacy Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Complete Remission and Overall Survival In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 6 |
NCT04402541 | Phase I | CB-5339 | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | AUS | 0 |
NCT04417517 | Phase Ib/II | Azacitidine + Evorpacept | A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) | Active, not recruiting | USA | ESP | 1 |
NCT04429191 | Phase I | JSP191 | JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation | Unknown status | USA | 0 |
NCT04487106 | Phase II | Azacitidine + Trametinib + Venetoclax | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT04493138 | Phase Ib/II | Azacitidine + Quizartinib | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | Recruiting | USA | 0 |
NCT04493164 | Phase II | CPX-351 + Ivosidenib Ivosidenib | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04522895 | Phase II | Enasidenib | IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT | Completed | DEU | 0 |
NCT04543305 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT04550442 | Phase Ib/II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT04581512 | Phase Ib/II | EP0042 | Study to Evaluate the Safety and Tolerability of EP0042 | Recruiting | NLD | GBR | AUS | 0 |
NCT04582864 | Phase II | Flotetuzumab | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | Terminated | USA | 0 |
NCT04609826 | Phase I | JNJ74856665 Azacitidine + JNJ74856665 JNJ74856665 + Venetoclax | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Active, not recruiting | GBR | FRA | ESP | 1 |
NCT04623996 | Phase Ib/II | TP-0184 | A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS | Terminated | USA | 0 |
NCT04628026 | Phase III | Cytarabine + Idarubicin + Venetoclax Cytarabine + Idarubicin Etoposide + Mitoxantrone + Venetoclax Etoposide + Mitoxantrone Cytarabine + Venetoclax Cytarabine + Daunorubicin + Venetoclax Cytarabine + Daunorubicin | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | Recruiting | DEU | 0 |
NCT04639024 | Phase II | Camidanlumab tesirine | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Terminated | USA | 0 |
NCT04655755 | Phase Ib/II | Decitabine and Cedazuridine + Venetoclax | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT04708054 | Phase II | Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | Recruiting | USA | 0 |
NCT04712942 | Phase II | Azacitidine + MLN4924 Azacitidine | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | Completed | DEU | 0 |
NCT04730258 | Phase Ib/II | CFI-400945 CFI-400945 + Decitabine Azacitidine + CFI-400945 | A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML (TWT-202) | Recruiting | USA | CAN | 1 |
NCT04734990 | Phase Ib/II | Azacitidine + Seclidemstat | Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT04771130 | Phase Ib/II | Azacitidine + BGB-11417 | A Study of BGB-11417 in Participants With Myeloid Malignancies | Recruiting | USA | NZL | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
NCT04797780 | Phase III | Azacitidine Azacitidine + Tamibarotene | Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome | Recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | 0 |
NCT04798339 | Phase Ib/II | Canakinumab + Darbepoetin Alfa | Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | Recruiting | USA | 0 |
NCT04810611 | Phase I | NIS793 Sabatolimab Canakinumab + Sabatolimab NIS793 + Sabatolimab Canakinumab | Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | Terminated | USA | ITA | ISR | ESP | AUS | 2 |
NCT04812548 | Phase II | Azacitidine + Sabatolimab + Venetoclax | A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3) | Terminated | ITA | HUN | GRC | FRA | ESP | DEU | BEL | 0 |
NCT04823624 | Phase II | Sabatolimab | MBG453 in Lower Risk MDS | Recruiting | USA | 0 |
NCT04874194 | Phase Ib/II | Omacetaxine mepesuccinate + Venetoclax | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | Completed | USA | 0 |
NCT04878432 | Phase II | Azacitidine + Decitabine and Cedazuridine + Sabatolimab Azacitidine + Decitabine + Sabatolimab | STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | Completed | USA | 0 |
NCT04891757 | Phase I | FHD-286 | FHD-286 in Subjects With Advanced Hematologic Malignancies | Recruiting | USA | 0 |
NCT04912063 | Phase I | Azacitidine + Lemzoparlimab Azacitidine + Lemzoparlimab + Venetoclax | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitdine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | Terminated | USA | ITA | ISR | ESP | DEU | AUS | 1 |
NCT04937166 | Phase I | Azacitidine + DSP107 + Venetoclax | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT04951778 | Phase I | CC-91633 | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes | Recruiting | USA | GBR | ESP | CAN | AUS | 0 |
NCT04953780 | Phase I | Calaspargase pegol-mknl + Cytarabine + Idarubicin | 2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML | Active, not recruiting | USA | 0 |
NCT04964518 | Phase I | APG-2575 + Azacitidine | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | USA | AUS | 0 |
NCT05005299 | Phase I | Cyclophosphamide + Fludarabine + Venetoclax | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) | Recruiting | AUS | 0 |
NCT05010122 | Phase Ib/II | Decitabine and Cedazuridine + Gilteritinib + Venetoclax | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT05024994 | Phase II | E7820 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | Active, not recruiting | USA | 0 |
NCT05030675 | Phase I | Fostamatinib | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents | Completed | USA | 0 |
NCT05086315 | Phase Ib/II | SAR443579 | First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | Recruiting | USA | NLD | FRA | AUS | 1 |
NCT05107856 | Phase I | PRT1419 | A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies | Terminated | USA | 0 |
NCT05146739 | Phase I | Cytarabine + Fludarabine + Uproleselan | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane | Active, not recruiting | USA | 0 |
NCT05148234 | Phase Ib/II | BMS-986253 + Decitabine and Cedazuridine BMS-986253 | A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes | Terminated | USA | 0 |
NCT05168202 | Phase I | Azacitidine + CC-95251 CC-95251 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes | Completed | USA | SWE | NOR | ITA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT05168904 | Phase Ib/II | CYC065 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | Suspended | USA | 0 |
NCT05178342 | Phase II | CA-4948 | Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS) | Terminated | DEU | 0 |
NCT05209152 | Phase I | AMG 176 + Azacitidine AMG 176 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia | Completed | USA | 0 |
NCT05275439 | Phase I | Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Active, not recruiting | USA | GBR | CAN | 0 |
NCT05282459 | Phase Ib/II | Enasidenib | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | Active, not recruiting | USA | 0 |
NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Recruiting | USA | 0 |
NCT05308264 | Phase Ib/II | R289 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Recruiting | USA | 0 |
NCT05362773 | Phase I | MGD024 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT05365035 | Phase II | Azacitidine + Venetoclax Cladribine + Cytarabine + Venetoclax | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | Recruiting | USA | 0 |
NCT05379166 | Phase II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05424380 | Phase I | GSK3745417 | A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS | Terminated | NLD | ITA | ESP | DEU | CAN | 0 |
NCT05428969 | Phase Ib/II | Azacitidine + FP-1305 Azacitidine + FP-1305 + Venetoclax | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) | Recruiting | USA | FIN | 0 |
NCT05455294 | Phase I | Decitabine + Navitoclax + Venetoclax | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT05457010 | Phase I | ACLX-002 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | Recruiting | USA | 0 |
NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT05564390 | Phase II | Cytarabine + Venetoclax Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax Cytarabine + Daunorubicin Cytarabine Azacitidine + Gilteritinib + Venetoclax Azacitidine + Venetoclax CPX-351 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Recruiting | USA | CAN | 1 |
NCT05564650 | Phase Ib/II | Decitabine + Navitoclax + Venetoclax | Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT05583552 | Phase II | Imetelstat | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) | Recruiting | FRA | DEU | AUS | 0 |
NCT05601726 | Phase I | ABD-3001 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY) | Recruiting | FRA | 0 |
NCT05636514 | Phase I | Decitabine and Cedazuridine + Defactinib | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS) | Recruiting | AUS | 0 |
NCT05673057 | Phase Ib/II | MP0533 | Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | NLD | LTU | FRA | CHE | 0 |
NCT05732103 | Phase Ib/II | CTX-712 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Recruiting | USA | 0 |
NCT05756322 | Phase Ib/II | LBS-007 | The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Recruiting | USA | AUS | 1 |
NCT05766514 | Phase II | Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | Not yet recruiting | USA | 0 |
NCT05775406 | Phase I | KT-253 | Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | Active, not recruiting | USA | 0 |
NCT05782127 | Phase Ib/II | Azacitidine + Venetoclax | Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes | Recruiting | FRA | 0 |
NCT05787496 | Phase I | NC525 | A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT05823571 | Phase I | Itacitinib | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Recruiting | USA | 0 |
NCT05829226 | Phase I | LYT-200 | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | Recruiting | USA | 0 |
NCT05834244 | Phase I | Azacitidine + Venetoclax | A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | Recruiting | USA | 0 |
NCT05835011 | Phase II | Decitabine and Cedazuridine + Hu5F9-G4 | A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) | Terminated | USA | 0 |
NCT05903274 | Phase I | JSP191 | JSP191 (Briquilimab) in Subjects With LR-MDS | Recruiting | USA | 0 |
NCT05918055 | Phase Ib/II | Decitabine and Cedazuridine + Eltanexor | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes | Recruiting | USA | 0 |
NCT05933070 | Phase I | INKmune | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL) | Terminated | GRC | GBR | 0 |
NCT05955261 | Phase II | Azacitidine + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + Venetoclax Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + mitoxantrone hydrochloride + Venetoclax Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Gilteritinib + mitoxantrone hydrochloride + Venetoclax | A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05961839 | Phase I | SGR-2921 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT06034275 | Phase I | VIP943 | Study of VIP943 in Subjects With Advanced CD123 pos Hematologic Malignancies | Recruiting | USA | 0 |
NCT06129734 | Phase Ib/II | Decitabine + Venetoclax | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | Not yet recruiting | USA | 0 |
NCT06146257 | Phase I | GLB-001 | A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | Recruiting | USA | 0 |
NCT06179511 | Phase Ib/II | AZD9829 | Study of AZD9829 in CD123+ Hematological Malignancies | Recruiting | USA | ITA | GBR | ESP | DEU | AUS | 4 |
NCT06196203 | Phase II | Azacitidine AK117 + Azacitidine | A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Recruiting | USA | 1 |
NCT06247787 | Phase I | Hydrocortisone Sodium Succinate + Methotrexate Leucovorin Cytarabine + Hydrocortisone Sodium Succinate Cytarabine + Fludarabine + Imetelstat | A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Recruiting | USA | 0 |
NCT06268574 | Phase II | RVU120 | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52) | Recruiting | POL | ITA | FRA | ESP | CAN | 0 |
NCT06284460 | Phase Ib/II | ASTX029 ASTX029 + Decitabine and Cedazuridine | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | Withdrawn | USA | 0 |
NCT06285890 | Phase I | Azacitidine + HC-7366 + Venetoclax | Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT06287944 | Phase I | Melphalan Fludarabine Sirolimus 225Ac-DOTA-Daratumumab Tacrolimus | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | Not yet recruiting | USA | 0 |
NCT06291987 | Phase I | Ivosidenib + Ruxolitinib | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) | Recruiting | USA | 0 |
NCT06297629 | Phase II | Decitabine and Cedazuridine | A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | Withdrawn | USA | 0 |
NCT06297941 | Phase I | REM-422 | Study of REM-422 in Patients With AML or Higher Risk MDS | Recruiting | USA | 0 |
NCT06303193 | Phase I | Pacritinib | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | Not yet recruiting | USA | 0 |
NCT06325748 | Phase I | SENTI-202 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Recruiting | USA | AUS | 0 |
NCT06326463 | Phase I | CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT06337331 | Phase II | Busulfan + Decitabine + Fludarabine + Venetoclax | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | Withdrawn | USA | 0 |
NCT06359002 | Phase I | BYON4413 | Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. | Recruiting | NLD | ESP | BEL | 0 |
NCT06372717 | Phase Ib/II | APL-4098 APL-4098 + Azacitidine | A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS | Recruiting | AUS | 0 |
NCT06399640 | Phase I | Eltanexor + Venetoclax | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT06419634 | Phase I | BMS-986497 | Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | CAN | 0 |
NCT06445907 | Phase I | Azacitidine + Q702 + Venetoclax | Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |
NCT06454409 | Phase I | Azacitidine + Regorafenib + Venetoclax | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |
NCT06492707 | Phase I | ST-067 | DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial | Recruiting | USA | 0 |
NCT06501196 | Phase I | BH-30236 | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT06522373 | Phase I | TAK-169 | Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease | Withdrawn | 0 | |
NCT06543381 | Phase I | Olutasidenib | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | Recruiting | USA | 0 |
NCT06548230 | Phase Ib/II | Azacitidine + Nidanilimab + Venetoclax Nidanilimab | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | Not yet recruiting | USA | 0 |
NCT06566742 | Phase II | Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | Not yet recruiting | USA | 0 |
NCT06572631 | Phase I | Decitabine + NEXI-001 T Cells | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor | Not yet recruiting | USA | 0 |
NCT06597734 | Phase II | Decitabine and Cedazuridine + Olutasidenib Azacitidine + Olutasidenib Decitabine + Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | Not yet recruiting | USA | 0 |
NCT06616636 | Phase I | Azacitidine + PC14586 Azacitidine + PC14586 + Venetoclax | A Phase Ib Study of Rezatapopt in Combination with Azacitidine or Azacitidine and Venetoclax in Patients with TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | Not yet recruiting | USA | 0 |
NCT06630221 | Phase II | Eltrombopag | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | Not yet recruiting | USA | 0 |
NCT06641414 | Phase III | Azacitidine APG-2575 + Azacitidine | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). | Not yet recruiting | USA | 1 |
NCT06668584 | Phase Ib/II | Olutasidenib | A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients with IDH1-mutated Myeloid Malignancies | Not yet recruiting | USA | 0 |